Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 20/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 20/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 18/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 18/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21380924 | 0.81 | BPTF (0.38) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL21398937 | 0.70 | CHRNB2 (0.43) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL23173103 | 0.70 | CHRNB2 (0.43) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL21380794 | 0.69 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL21399258 | 0.67 | CHRNB2 (0.40) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL21380915 | 0.65 | JAK2 (0.39) | — | |
| SCHEMBL21380845 | 0.64 | JAK2 (0.41) | — | |
| SCHEMBL21399193 | 0.63 | CHRNB2 (0.44) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL8212349 | 0.61 | CHRNB2 (0.67) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL8222386 | 0.61 | CHRNB2 (0.67) | CHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230010886-A1 | SHP2 INHIBITORS AND USES THEREOF | Suzhou Puhe BioPharma Co., Ltd. (CN) | 2023-01-12 | — | — | US | claimed |
| WO-2021061515-A1 | SHP2 INHIBITORS AND USES THEREOF | SYNBLIA THERAPEUTICS, INC. (US) | 2021-04-01 | — | — | WO | claimed |
| EP-3768664-A1 | SHP2 INHIBITORS AND USES THEREOF | Synblia Therapeutics, Inc. (US) | 2021-01-27 | — | — | EP | claimed |
| US-10561655-B2 | SHP2 inhibitors and uses thereof | SYNBLIA THERAPEUTICS, INC. (US) | 2020-02-18 | — | — | US | claimed |
| WO-2019182960-A1 | SHP2 INHIBITORS AND USES THEREOF | SYNBLIA THERAPEUTICS, INC. (US) | 2019-09-26 | — | — | WO | claimed |
| US-20230010886-A1 | SHP2 INHIBITORS AND USES THEREOF | Suzhou Puhe BioPharma Co., Ltd. (CN) | 2023-01-12 | — | — | US | disclosed |
| WO-2021061515-A1 | SHP2 INHIBITORS AND USES THEREOF | SYNBLIA THERAPEUTICS, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| EP-3768664-A1 | SHP2 INHIBITORS AND USES THEREOF | Synblia Therapeutics, Inc. (US) | 2021-01-27 | — | — | EP | disclosed |
| US-10561655-B2 | SHP2 inhibitors and uses thereof | SYNBLIA THERAPEUTICS, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| WO-2019182960-A1 | SHP2 INHIBITORS AND USES THEREOF | SYNBLIA THERAPEUTICS, INC. (US) | 2019-09-26 | — | — | WO | disclosed |
| US-20190290649-A1 | SHP2 INHIBITORS AND USES THEREOF | Suzhou Puhe BioPharma Co., Ltd. (CN) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230010886-A1 | SHP2 INHIBITORS AND USES THEREOF | PTPN1, PTPN7, PTPN18 | CHRNB2 4738/4885CHRNA4 4859/4885CHRNB4 4781/4885 |
| US-20190290649-A1 | SHP2 INHIBITORS AND USES THEREOF | PTPN1, PTPN7, PTPN18 | CHRNB2 4738/4885CHRNA4 4859/4885CHRNB4 4781/4885 |
| US-10561655-B2 | SHP2 inhibitors and uses thereof | PTPN1, PTPN7, PTPN18 | CHRNB2 4738/4885CHRNA4 4859/4885CHRNB4 4781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.